- Home
- XERS vs IGD Comparison
XERS vs IGD Comparison
Compare XERS & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- IGD
- Stock Information
- Founded
- XERS 2005
- IGD N/A
- Country
- XERS United States
- IGD United States
- Employees
- XERS N/A
- IGD N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- IGD Trusts Except Educational Religious and Charitable
- Sector
- XERS Health Care
- IGD Finance
- Exchange
- XERS Nasdaq
- IGD Nasdaq
- Market Cap
- XERS 526.3M
- IGD 432.2M
- IPO Year
- XERS 2018
- IGD N/A
- Fundamental
- Price
- XERS $3.70
- IGD $5.44
- Analyst Decision
- XERS Buy
- IGD
- Analyst Count
- XERS 3
- IGD 0
- Target Price
- XERS $4.87
- IGD N/A
- AVG Volume (30 Days)
- XERS 1.6M
- IGD 215.3K
- Earning Date
- XERS 03-05-2025
- IGD 01-01-0001
- Dividend Yield
- XERS N/A
- IGD 9.15%
- EPS Growth
- XERS N/A
- IGD N/A
- EPS
- XERS N/A
- IGD N/A
- Revenue
- XERS $187,361,000.00
- IGD N/A
- Revenue This Year
- XERS $24.64
- IGD N/A
- Revenue Next Year
- XERS $19.04
- IGD N/A
- P/E Ratio
- XERS N/A
- IGD N/A
- Revenue Growth
- XERS 22.72
- IGD N/A
- 52 Week Low
- XERS $1.69
- IGD $4.60
- 52 Week High
- XERS $3.87
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- XERS 62.63
- IGD 47.45
- Support Level
- XERS $3.47
- IGD $5.31
- Resistance Level
- XERS $3.78
- IGD $5.45
- Average True Range (ATR)
- XERS 0.16
- IGD 0.05
- MACD
- XERS 0.03
- IGD -0.00
- Stochastic Oscillator
- XERS 84.13
- IGD 54.55
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.